FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody or its antigen-binding fragment for specific binding to PRAME protein. The use of the specified antibody is disclosed for the production of a drug for the targeted therapy of PRAME-expressing tumor diseases; for the indication of PRAME protein expression in samples of human tissues and cells; for the stimulation of antibody-dependable cytotoxicity against PRAME-expressing tumors; for the reduction in the growth rate of PRAME-expressing tumors.
EFFECT: invention allows for the effective treatment of diseases associated with PRAME factor.
9 cl, 3 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED 5D3HU ANTIBODY BINDING TO THE PRAME TUMOUR ANTIGEN, DNA FRAGMENTS ENCODING SAID ANTIBODY, AND ANTIGEN-BINDING FRAGMENT OF THE ANTIBODY | 2020 |
|
RU2761876C1 |
| HUMANIZED ANTIBODY 6H8HU, BINDING TO TUMOUR ANTIGEN PRAME, DNA FRAGMENTS CODING SAID ANTIBODY AND ANTIGEN-BINDING ANTIBODY FRAGMENT | 2020 |
|
RU2768737C1 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | 2013 |
|
RU2668824C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
| HUMAN TUMOUR-ASSOCIATED MONOCLONAL ANTIBODY | 2008 |
|
RU2488593C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING CANCER | 2009 |
|
RU2533460C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2011 |
|
RU2598258C2 |
